Nucala_Precertification_Request
Aetna precertification request form to collect patient, prescriber, dispensing, diagnosis, and clinical information for authorization review for Nucala (mepolizumab) in multiple labeled indications (asthma, CRSwNP, EGPA, HES). It defines required fields and clinical questions to support prior authorization review; it does not itself state coverage criteria or billing codes.
No material changes — this is an administrative precertification form with no material clinical/coverage changes.
Policy overview & purpose
This is an Aetna precertification request form titled Nucala (mepolizumab) Injectable Medication Precertification Request used to collect patient, prescriber, dispensing/administration, product, diagnosis (ICD code) and indication-specific clinical information needed for utilization review across labeled indications including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.